rheumatology
Autoinflammatory diseases

Infliximab biosimilar uptake incentives take effect for RA and AS


PBS listings for infliximab have been amended from 1 November to encourage the use of biosimilar brands Inflectra and Renflexis for ankylosing spondylitis and rheumatoid arthritis As part of the government’s biosimilar uptake drivers strategy to encourage use of cheaper alternatives to the originator Remicade brand, prescriptions for the biosimilar brands in public hospitals can ...

Already a member?

Enter your email to keep reading.


OR